Submitted to: Research Workers in Animal Diseases Conference Proceedings
Publication Type: Abstract Only
Publication Acceptance Date: 10/1/2006
Publication Date: 12/3/2006
Citation: Baldwin, C., Lunney, J.K., Lillehoj, H.S., Lebresh, J., Horohov, D., Hansen, J., Miller, N., Bengton, E., Chinchar, G., Wilson, M., Wagner, B. 2006. Us veterinary immune reagents network. In: R. Ellis Ed., Porceedings of the 2006 CRWAD meeting, Chicago, IL, December 3-5, 2006. Blackwell Publishing. p. 71
Technical Abstract: A major obstacle to advances in veterinary immunology and disease control is the lack of sufficient immunological reagents specific for ruminants, swine, poultry, equine, and aquaculture species. Sets of reagents, i.e. monoclonal (mAb) and polyclonal antibodies (Ab), that can identify the major leukocyte subsets (T and B lymphocytes, NK cells, macrophages, dendritic cells, neutrophils) are needed to evaluate changes during disease and following vaccination and to give scientists the ability to manipulate these cell populations in order to evaluate their roles in protective immunity as well as in immunopathology. In addition, it is crucial to have recombinant cytokines and chemokines and Ab to them and their receptors to understand their contributions to inflammation and protective immunity. Reagents to identify immunoglobulin isotypes are needed since Ig isotypes differ from one another functionally and, thus, with regard to their effect on disease outcome. Development of the above reagents will enhance the safety of the nation's agriculture and food supply by aiding in the development of vaccines or therapies. A broad community plan to begin to systematically address the immunological reagent gap has been initiated with a goal of 20 reagents per species group. The reagents produced will include bioactive recombinant cytokines and chemokine proteins (expressed using mammalian cells, Pichia pastoris or E. coli systems) as well as polyclonal Ab and mAb to them, their receptors, as well as mAb to Ig isotypes, T cell receptors (TCR), Toll like receptors (TLR), and other CD molecules. Our goal is to produce antibodies that function in Elisa and ELISpot assays, for intracellular staining, for blocking function and signaling, and that are useful in flow cytometric applications as well as in fixed tissue sections. Products developed in this proposal will benefit a large group of researchers, including veterinary immunologists, pathologists, and microbiologists.